

HR 6897

Synthetic Biology and Active Pharmaceutical Ingredients Act

Congress: 118 (2023–2025, Ended)

Chamber: House

Policy Area: Health

Introduced: Dec 22, 2023

Current Status: Referred to the House Committee on Armed Services.

Latest Action: Referred to the House Committee on Armed Services. (Dec 22, 2023)

Official Text: <https://www.congress.gov/bill/118th-congress/house-bill/6897>

Sponsor

Name: Rep. Slotkin, Elissa [D-MI-7]

Party: Democratic • State: MI • Chamber: Senate

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Gallagher, Mike [R-WI-8]	R · WI		Dec 22, 2023

Committee Activity

Committee	Chamber	Activity	Date
Armed Services Committee	House	Referred To	Dec 22, 2023

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Dec 22, 2023)

Synthetic Biology and Active Pharmaceutical Ingredients Act

This bill requires the Department of Defense (DOD) to establish a pilot program to support domestic manufacturing of critical pharmaceutical ingredients and their components through certain novel technology.

Specifically, DOD must establish a three-year program that uses technology involving synthetic biology to support domestic manufacturing of pharmaceutical ingredients and related incorporated materials that (1) are not available in a sufficient quantity or quality domestically, and (2) are strategically important to the United States.

## Actions Timeline

---

- **Dec 22, 2023:** Introduced in House
- **Dec 22, 2023:** Referred to the House Committee on Armed Services.